A team from the University of Hong Kong has mapped the deep biological wiring that aging and cancer share, arguing that four master signalling systems — nutrient sensing (mTOR/AMPK), DNA-damage and stress responses, chronic inflammation, and sirtuin-driven epigenetics — sit at the crossroads of both. Their central claim is a paradox: aging both drives cancer (through genomic chaos and inflammation) and restrains it (through telomere shortening, stem-cell exhaustion, and senescence). The practical payoff they propose is drug repurposing — taking well-validated cancer drugs and testing them as anti-aging agents, and vice versa — because both fields keep converging on the same molecular targets.
For decades aging and cancer have been studied as separate problems. This review argues they are two outputs of the same underlying machinery, and that treating them as one problem could accelerate both fields.
The “Big Idea” is that aging is not a simple on-ramp to cancer. The authors highlight a genuine paradox visible even in population data: cancer risk climbs steeply after age 65, yet in the very oldest group (85+) the risk of developing several cancers actually dips. The explanation, they argue, is that aging pushes in two directions at once. Some hallmarks of aging — genomic instability, epigenetic drift, mitochondrial failure, gut dysbiosis, and the smouldering, lifelong inflammation researchers call “inflammaging” — actively fertilise tumours. But other hallmarks of aging actively starve them: telomeres shorten until cells can no longer divide indefinitely, stem cells become exhausted and lose the plasticity tumours exploit, and senescence slams the brakes on cell division. Cancer and aging, in other words, are locked in a tug-of-war.
Where this becomes actionable is in the shared control panel. The insulin/IGF-1/PI3K/AKT/mTOR axis, when overactive, both accelerates aging and feeds tumours — which is why rapamycin (an mTOR blocker) extends mouse lifespan and is the parent of approved cancer drugs. Its metabolic mirror, AMPK, does the opposite: switched on by exercise, fasting, or metformin, it extends lifespan and generally suppresses tumours. The same doubling-up appears across DNA-repair genes (TP53, ATM), the anti-inflammatory targets (NF-kB, NLRP3, IL-6), and the sirtuin/NAD+ epigenetic system.
The authors’ blunt observation is that anti-cancer drug development is years ahead of anti-aging development for the very same targets. Dozens of pathway drugs are already FDA-approved for tumours; almost none are approved for aging. Their proposed shortcut: repurpose the approved oncology arsenal — rapamycin analogues, metformin, senolytics such as dasatinib-plus-quercetin, PI3K inhibitors — into geroprotectors, and mine aging biology for new tumour targets.
The catch, which the review is candid about, is that most anti-aging evidence for these pathways still lives in worms, flies, and mice. The human anti-aging data are thin, early, and mostly about surrogate markers (immune response, muscle, skin) rather than hard lifespan outcomes.
Actionable Insights
The review is a map, not a prescription, and nearly all quantified effects come from animals. The take-home interventions it repeatedly returns to, with the actual magnitudes from the cited primary studies:
- mTOR inhibition (rapamycin/rapalogs): In the NIA Interventional Testing Program (Miller 2014), late-life rapamycin raised maximal lifespan by +23% in male and +26% in female genetically heterogeneous mice — the single most robust datapoint here. Human data show only improved flu-vaccine response and fewer exhausted T-cells, not lifespan.
- AMPK activation (metformin, fasting, exercise): Dietary restriction acting through AMPK-FOXO extended C. elegans lifespan by >30%; in primates metformin was associated with a ~6-year attenuation of brain-ageing parameters. Human lifespan effect: unproven.
- PI3Ka inhibition (alpelisib): ~10% average lifespan extension in middle-aged mice (Hedges 2023).
Bottom line for a biohacker: the directionally validated levers are the familiar ones — restrain mTOR, activate AMPK, clear senescent cells — but the honest human effect size on longevity is currently unquantifiable, because the hard human endpoints do not exist yet.
Context / Source
- Open Access Paper: Aging and cancer: current understandings and future perspectives, Published: 08 July 2026.
- Authors / Institution / Country: Qiucheng Li, Yau-Tuen Chan, Junyu Wu et al.; corresponding author Ning Wang. School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong S.A.R., PR China.
- Journal: Signal Transduction and Targeted Therapy (Nature Portfolio), 2026.
- Article type: Review article (not primary research).
- Impact Evaluation: The impact score of this journal is ~40 (JCR), evaluated against a typical high-end range of 0–60+ for top general and translational science journals, therefore this is an ELITE impact journal.